MDxHealth S.A.(MDXH)Earnings, Financials & Key Ratios
MDXH•NASDAQ
$2.02
$104M mkt cap·Price updated May 6, 2026
AboutMDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.Show more
- Revenue$90M+28.3%
- EBITDA-$17M+18.5%
- Net Income-$38M+11.7%
- EPS (Diluted)-1.16+30.1%
- Gross Margin61.23%-2.2%
- EBITDA Margin-18.53%+36.5%
- Operating Margin-27.45%+29.5%
- Net Margin-42.28%+31.1%
- ROE-345.31%+33.8%
- ROIC-68.42%+0.4%
- Debt/Equity4.05-29.3%
- Interest Coverage-3.24+31.6%
MDXH Key Insights
MDxHealth S.A. (MDXH) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 50.2%
✗Weaknesses
- ✗High debt to equity ratio of 4.0x
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 7 (bottom 7%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 87.8% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MDXH Price & Volume
MDxHealth S.A. (MDXH) stock price & volume — 10-year historical chart
Loading chart...
MDXH Growth Metrics
MDxHealth S.A. (MDXH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years22.87%
5 Years50.19%
3 Years59.39%
TTM83.19%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM22.48%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM68.51%
Return on Capital
10 Years-53.28%
5 Years-55.09%
3 Years-31.85%
Last Year-22.05%
MDXH Recent Earnings
MDxHealth S.A. (MDXH) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 10/12 qtrs (100%)
Q4 2025Latest
Nov 12, 2025EPS
$0.16
Est $0.12
-33.3%
Revenue
$53M
Est $26M
+103.2%
Q3 2025
Aug 5, 2025EPS
$0.15
Est $0.13
-15.4%
Revenue
$27M
Est $26M
+1.1%
Q2 2025
May 14, 2025EPS
$0.19
Est $0.13
-46.2%
Revenue
$48M
Est $25M
+91.0%
Q1 2025
Feb 26, 2025EPS
$0.14
Est $0.21
+33.3%
Revenue
$25M
Est $23M
+9.1%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 12, 2025 | $0.16vs $0.12-33.3% | $53Mvs $26M+103.2% |
| Q3 2025 | Aug 5, 2025 | $0.15vs $0.13-15.4% | $27Mvs $26M+1.1% |
| Q2 2025 | May 14, 2025 | $0.19vs $0.13-46.2% | $48Mvs $25M+91.0% |
| Q1 2025 | Feb 26, 2025 | $0.14vs $0.21+33.3% | $25Mvs $23M+9.1% |
Based on last 12 quarters of dataView full earnings history →
MDXH Peer Comparison
MDxHealth S.A. (MDXH) competitors in Molecular and Genetic Diagnostics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 VCYT | 3.29B | 41.19 | 50.23 | 16.01% | 16.25% | 6.86% | 0.03 | |
 NTRA | 29.58B | 215.09 | -140.58 | 56.75% | -14.61% | -24.69% | 0.16 | |
 QDEL | 746.18M | 10.96 | -0.66 | -1.89% | -45.57% | -56.31% | 1.46 | |
 ILMN | 21.66B | 142.58 | 26.16 | -0.78% | 19.43% | 32.84% | 0.94 | |
 PACB | 516.17M | 1.71 | -1.60 | -23.19% | -325.8% | -13.95% | 1.33 | |
 CDNA | 1.08B | 20.94 | -52.35 | 13.79% | -1.98% | -2.61% | 0.06 | |
 PRME | 615.68M | 3.41 | -2.53 | 55.28% | -43.42% | -178.61% | 0.96 |
Compare MDXH vs Peers
MDxHealth S.A. (MDXH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MDXH Income Statement
MDxHealth S.A. (MDXH) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 29.87M | 40.51M | 28.34M | 11.79M | 18.46M | 22.24M | 37.05M | 70.19M | 90.05M | 196.47M |
| Revenue Growth % | 70.99% | 35.63% | -30.04% | -58.41% | 56.64% | 20.47% | 66.62% | 89.43% | 28.29% | 83.19% |
| Cost of Goods Sold | 10.1M | 10.2M | 11.65M | 11.93M | 10.42M | 11.68M | 17.84M | 26.26M | 34.91M | 66.51M |
| COGS % of Revenue | 33.83% | 25.19% | 41.12% | 101.22% | 56.42% | 52.5% | 48.13% | 37.42% | 38.77% | - |
| Gross Profit | 19.76M▲ 0% | 30.3M▲ 53.3% | 16.69M▼ 44.9% | -144K▼ 100.9% | 8.04M▲ 5686.1% | 10.56M▲ 31.3% | 19.22M▲ 81.9% | 43.93M▲ 128.6% | 55.14M▲ 25.5% | 125.41M▲ 0% |
| Gross Margin % | 66.17% | 74.81% | 58.88% | -1.22% | 43.58% | 47.5% | 51.87% | 62.58% | 61.23% | 63.83% |
| Gross Profit Growth % | 87.12% | 53.33% | -44.94% | -100.86% | 5686.11% | 31.33% | 81.93% | 128.57% | 25.52% | - |
| Operating Expenses | 32.61M | 42.58M | 48.78M | 43.02M | 35.17M | 37.41M | 57.12M | 71.26M | 79.86M | 154.92M |
| OpEx % of Revenue | 109.18% | 105.11% | 172.15% | 365.08% | 190.5% | 168.2% | 154.15% | 101.51% | 88.69% | - |
| Selling, General & Admin | 11.56M | 13.51M | 15.26M | 10.1M | 28.61M | 30.22M | 50.12M | 59.92M | 61.4M | 124.12M |
| SG&A % of Revenue | 38.69% | 33.34% | 53.85% | 85.74% | 155% | 135.87% | 135.26% | 85.37% | 68.18% | - |
| Research & Development | -332K | 1.83M | 1.81M | 9M | 4.54M | 5.59M | 7.56M | 6.38M | 10.55M | 11.57M |
| R&D % of Revenue | -1.11% | 4.51% | 6.39% | 76.34% | 24.61% | 25.13% | 20.39% | 9.08% | 11.72% | - |
| Other Operating Expenses | 21.39M | 27.25M | 31.71M | 23.92M | 2.01M | 1.6M | -559K | 4.96M | 7.92M | 4M |
| Operating Income | -12.85M▲ 0% | -12.27M▲ 4.5% | -32.1M▼ 161.5% | -43.17M▼ 34.5% | -27.12M▲ 37.2% | -26.84M▲ 1.0% | -37.9M▼ 41.2% | -27.33M▲ 27.9% | -24.72M▲ 9.5% | -32.39M▲ 0% |
| Operating Margin % | -43.01% | -30.3% | -113.27% | -366.3% | -146.93% | -120.69% | -102.28% | -38.93% | -27.45% | -16.48% |
| Operating Income Growth % | 10.68% | 4.45% | -161.51% | -34.49% | 37.17% | 1.04% | -41.2% | 27.9% | 9.53% | - |
| EBITDA | -11.13M | -10.06M | -29.16M | -39.75M | -23.79M | -23.8M | -32.99M | -20.47M | -16.68M | -15.28M |
| EBITDA Margin % | -37.25% | -24.83% | -102.9% | -337.28% | -128.88% | -107.04% | -89.03% | -29.16% | -18.53% | -7.78% |
| EBITDA Growth % | 17.59% | 9.58% | -189.87% | -36.31% | 40.15% | -0.06% | -38.59% | 37.96% | 18.49% | 71.41% |
| D&A (Non-Cash Add-back) | 1.72M | 2.21M | 2.94M | 3.42M | 3.33M | 3.04M | 4.91M | 6.86M | 8.04M | 16.02M |
| EBIT | -12.85M | -12.4M | -32.41M | -43.16M | -27.31M | -27.13M | -41.3M | -37.33M | -30.06M | -47.48M |
| Net Interest Income | -436K | -122K | -61K | -506K | -1.54M | -1.87M | -2.62M | -4.68M | -6.55M | -33.51M |
| Interest Income | 6K | 0 | 21K | 10K | 4K | 11K | 125K | 1.09M | 1.08M | 3.19M |
| Interest Expense | 0 | 122K | 82K | 516K | 1.54M | 1.88M | 2.74M | 5.77M | 7.63M | 34.85M |
| Other Income/Expense | -441K | -127K | -393K | -506K | -1.54M | -2.16M | -6.14M | -15.77M | -12.96M | -34.61M |
| Pretax Income | -13.29M▲ 0% | -12.4M▲ 6.7% | -32.49M▼ 162.0% | -43.67M▼ 34.4% | -28.66M▲ 34.4% | -29M▼ 1.2% | -44.04M▼ 51.9% | -43.1M▲ 2.1% | -37.69M▲ 12.6% | -74.03M▲ 0% |
| Pretax Margin % | -44.49% | -30.61% | -114.66% | -370.6% | -155.27% | -130.41% | -118.86% | -61.4% | -41.85% | -37.68% |
| Income Tax | -113K | -113K | -41K | -575K | 0 | 0 | 0 | 1K | 382K | -449K |
| Effective Tax Rate % | 0.85% | 0.91% | 0.13% | 1.32% | 0% | 0% | 0% | -0% | -1.01% | 0.61% |
| Net Income | -13.17M▲ 0% | -12.29M▲ 6.7% | -32.45M▼ 164.1% | -43.1M▼ 32.8% | -28.66M▲ 33.5% | -29M▼ 1.2% | -44.04M▼ 51.9% | -43.1M▲ 2.1% | -38.07M▲ 11.7% | -67.56M▲ 0% |
| Net Margin % | -44.11% | -30.33% | -114.51% | -365.72% | -155.27% | -130.41% | -118.86% | -61.4% | -42.28% | -34.39% |
| Net Income Growth % | 8.98% | 6.73% | -164.08% | -32.82% | 33.5% | -1.19% | -51.87% | 2.14% | 11.67% | 22.48% |
| Net Income (Continuing) | -13.17M | -12.29M | -32.45M | -43.1M | -28.66M | -29M | -44.04M | -43.1M | -38.07M | -73.58M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.86▲ 0% | -2.46▲ 14.0% | -5.63▼ 128.9% | -6.89▼ 22.4% | -3.44▲ 50.1% | -2.38▲ 30.8% | -2.78▼ 16.8% | -1.66▲ 40.3% | -1.16▲ 30.1% | -1.39▲ 0% |
| EPS Growth % | 18.52% | 13.99% | -128.86% | -22.38% | 50.07% | 30.81% | -16.81% | 40.29% | 30.12% | 68.51% |
| EPS (Basic) | -2.86 | -2.46 | -5.63 | -6.89 | -3.44 | -2.38 | -2.78 | -1.66 | -0.78 | - |
| Diluted Shares Outstanding | 4.61M | 4.99M | 5.76M | 6.26M | 8.32M | 12.19M | 15.87M | 25.91M | 48.67M | 48.47M |
| Basic Shares Outstanding | 4.61M | 4.99M | 5.76M | 6.26M | 8.32M | 12.19M | 15.87M | 25.91M | 48.67M | 48.47M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
MDXH Balance Sheet
MDxHealth S.A. (MDXH) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 51.49M | 39.32M | 47.86M | 30.91M | 23.09M | 66.61M | 29.15M | 38.16M | 66.89M | 53.78M |
| Cash & Short-Term Investments | 30.51M | 16.83M | 26.2M | 22.1M | 15.95M | 58.59M | 15.6M | 22.38M | 46.8M | 32.81M |
| Cash Only | 30.51M | 16.83M | 26.2M | 22.05M | 15.95M | 58.5M | 15.5M | 22.38M | 46.8M | 32.81M |
| Short-Term Investments | 0 | 0 | 0 | 51K | 0 | 89K | 101K | 0 | 0 | 0 |
| Accounts Receivable | 18.54M | 19.93M | 19.13M | 6.64M | 3.89M | 4.58M | 9.36M | 11.27M | 14.53M | 15.71M |
| Days Sales Outstanding | 226.51 | 179.59 | 246.42 | 205.81 | 76.99 | 75.2 | 92.17 | 58.61 | 58.9 | 25.53 |
| Inventory | 1.48M | 1.92M | 1.81M | 1.19M | 2.32M | 1.91M | 2.33M | 2.78M | 3.87M | 3.66M |
| Days Inventory Outstanding | 53.43 | 68.65 | 56.6 | 36.47 | 81.44 | 59.74 | 47.62 | 38.62 | 40.45 | 19.29 |
| Other Current Assets | -37K | 24K | 104K | 54K | 52K | 504K | 151K | 146K | 135K | 1.6M |
| Total Non-Current Assets | 16.23M | 19.2M | 17.61M | 9.72M | 8.77M | 8.47M | 89.99M | 90.97M | 90.43M | 86.85M |
| Property, Plant & Equipment | 2.26M | 2.57M | 2.07M | 2.45M | 3.71M | 5.02M | 7.89M | 9.95M | 12.98M | 12.14M |
| Fixed Asset Turnover | 13.22x | 15.77x | 13.66x | 4.81x | 4.98x | 4.43x | 4.69x | 7.06x | 6.94x | 17.63x |
| Goodwill | 1.15M | 1.15M | 1.15M | 0 | 0 | 0 | 35.93M | 35.93M | 35.93M | 35.93M |
| Intangible Assets | 12.83M | 15.49M | 14.39M | 7.27M | 5.06M | 3.45M | 46.17M | 44.34M | 40.59M | 37.95M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 763K | 936K | 3.8M |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 763K |
| Total Assets | 67.72M▲ 0% | 58.52M▼ 13.6% | 65.48M▲ 11.9% | 40.63M▼ 37.9% | 31.86M▼ 21.6% | 75.07M▲ 135.7% | 119.14M▲ 58.7% | 129.13M▲ 8.4% | 157.33M▲ 21.8% | 140.63M▲ 0% |
| Asset Turnover | 0.44x | 0.69x | 0.43x | 0.29x | 0.58x | 0.30x | 0.31x | 0.54x | 0.57x | 1.41x |
| Asset Growth % | 17.28% | -13.59% | 11.88% | -37.95% | -21.59% | 135.66% | 58.69% | 8.39% | 21.84% | 29.5% |
| Total Current Liabilities | 12.59M | 13.12M | 11.48M | 10.43M | 13.02M | 16.43M | 18.28M | 19.52M | 42.66M | 41.2M |
| Accounts Payable | 7.55M | 8.05M | 6.45M | 4.96M | 5.32M | 7.46M | 10.18M | 8.81M | 8M | 6.74M |
| Days Payables Outstanding | 272.62 | 288.16 | 202.14 | 151.7 | 186.42 | 233.07 | 208.3 | 122.45 | 83.66 | 48.95 |
| Short-Term Debt | 430K | 191K | 147K | 565K | 2.82M | 4.44M | 616K | 643K | 324K | 0 |
| Deferred Revenue (Current) | 3.54M | 3.82M | 4.36M | 0 | 3.22M | 0 | 0 | 472K | 0 | 0 |
| Other Current Liabilities | 1.08M | 883K | 402K | 909K | -2.31M | 961K | 2.33M | 2.9M | 26.41M | 33M |
| Current Ratio | 4.09x | 3.00x | 4.17x | 2.96x | 1.77x | 4.05x | 1.59x | 1.95x | 1.57x | 1.57x |
| Quick Ratio | 3.97x | 2.85x | 4.01x | 2.85x | 1.59x | 3.94x | 1.47x | 1.81x | 1.48x | 1.48x |
| Cash Conversion Cycle | 7.33 | -39.92 | 100.89 | 90.58 | -27.99 | -98.12 | -68.5 | -25.22 | 15.7 | -4.13 |
| Total Non-Current Liabilities | 2.39M | 1.86M | 1.88M | 10.48M | 12.99M | 11.74M | 91.54M | 102.4M | 99.83M | 100.31M |
| Long-Term Debt | 108K | 147K | 0 | 9.05M | 10.28M | 7.65M | 34.91M | 35.56M | 50.97M | 75.66M |
| Capital Lease Obligations | 0 | 376K | 262K | 735K | 2.02M | 2.62M | 3.09M | 3.58M | 7.41M | 20.97M |
| Deferred Tax Liabilities | 729K | 616K | 575K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.55M | 661K | 1.04M | 690K | 690K | 1.47M | 53.54M | 63.26M | 41.45M | 162.73M |
| Total Liabilities | 14.98M | 14.97M | 13.36M | 20.9M | 26.01M | 28.17M | 109.82M | 121.92M | 142.49M | 141.52M |
| Total Debt | 538K | 884K | 526K | 11M | 15.87M | 15.56M | 39.79M | 41.27M | 60.06M | 84.01M |
| Net Debt | -29.97M | -15.94M | -25.68M | -11.05M | -82K | -42.94M | 24.29M | 18.89M | 13.27M | 51.2M |
| Debt / Equity | 0.01x | 0.02x | 0.01x | 0.56x | 2.71x | 0.33x | 4.27x | 5.72x | 4.05x | 4.05x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -5.50x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -3.35x |
| Interest Coverage | - | -100.61x | -391.44x | -83.66x | -17.58x | -14.32x | -13.82x | -4.73x | -3.24x | -1.36x |
| Total Equity | 52.74M▲ 0% | 43.55M▼ 17.4% | 52.12M▲ 19.7% | 19.72M▼ 62.2% | 5.85M▼ 70.3% | 46.9M▲ 701.8% | 9.31M▼ 80.1% | 7.21M▼ 22.6% | 14.84M▲ 105.9% | -883K▲ 0% |
| Equity Growth % | 19.16% | -17.43% | 19.68% | -62.15% | -70.35% | 701.83% | -80.14% | -22.62% | 105.9% | 40.2% |
| Book Value per Share | 11.45 | 8.72 | 9.05 | 3.15 | 0.70 | 3.85 | 0.59 | 0.28 | 0.30 | -0.02 |
| Total Shareholders' Equity | 52.74M | 43.55M | 52.12M | 19.72M | 5.85M | 46.9M | 9.31M | 7.21M | 14.84M | -883K |
| Common Stock | 45.85M | 45.95M | 53.88M | 70.72M | 76.72M | 143.42M | 148.42M | 173.93M | 214.67M | 214.67M |
| Retained Earnings | -98.8M | -111.09M | -143.54M | -186.64M | -215.3M | -244.3M | -288.35M | -331.45M | -369.51M | -386.1M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -686K | 1.24M | -1.17M | -704K | 8.08M | -5.39M | -3.94M | 11.55M | -615K | -829K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MDXH Cash Flow Statement
MDxHealth S.A. (MDXH) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -16.59M | -10.49M | -28.54M | -22.29M | -20.24M | -22.55M | -34.12M | -21.5M | -18.53M | -18.53M |
| Operating CF Margin % | -55.53% | -25.89% | -100.72% | -189.13% | -109.66% | -101.39% | -92.08% | -30.63% | -20.58% | - |
| Operating CF Growth % | -15.22% | 36.76% | -172.12% | 21.91% | 9.17% | -11.38% | -51.31% | 36.99% | 13.8% | 122.97% |
| Net Income | -12.85M | -12.27M | -32.1M | -43.17M | -27.12M | -26.84M | -37.9M | -27.33M | -24.72M | -67.56M |
| Depreciation & Amortization | 1.72M | 1.89M | 2.94M | 3.42M | 3.33M | 3.04M | 4.91M | 6.86M | 8.04M | 16.02M |
| Stock-Based Compensation | 568K | 943K | 1.01M | 872K | 1.29M | 1.22M | 867K | 665K | 1.73M | 3.47M |
| Deferred Taxes | 113K | -14K | 0 | 6.29M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -12K | -25K | -97K | 1K | 299K | -325K | -429K | 421K | 286K | -899.32K |
| Working Capital Changes | -6.13M | -1M | -291K | 10.29M | 1.95M | 360K | -1.56M | -2.12M | -3.86M | -13.4M |
| Change in Receivables | -7.57M | -1.43M | 717K | 12.19M | 2.85M | -1.38M | -5.12M | -1.68M | -3.23M | -6.59M |
| Change in Inventory | -52K | -440K | 112K | 615K | -1.13M | 413K | -416K | -452K | -1.09M | -2.92M |
| Change in Payables | 1.49M | 867K | -1.12M | -2.51M | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -5.32M | -6.05M | -1.34M | -73K | -537K | -885K | -29.04M | -3.93M | -1.64M | -23.56M |
| Capital Expenditures | -4.88M | -4.86M | -1.34M | -73K | -537K | -896K | -2.79M | -2.75M | -1.19M | -2.51M |
| CapEx % of Revenue | 16.36% | 12% | 4.75% | 0.62% | 2.91% | 4.03% | 7.53% | 3.91% | 1.32% | - |
| Acquisitions | 0 | -1.1M | 0 | 0 | 0 | 0 | -25M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -431K | -88K | -912K | 0 | 0 | 11K | -1.25M | -1.18M | -448K | -21.05M |
| Cash from Financing | 21.09M | 573K | 41.67M | 17.96M | 14.29M | 66.5M | 20.72M | 32.28M | 44.6M | 31.5M |
| Debt Issued (Net) | 80K | 346K | -358K | 8.71M | 1.49M | -1.06M | 22.13M | -3.27M | 11.59M | 7.74M |
| Equity Issued (Net) | 1000K | 0 | 1000K | 1000K | 1000K | 1000K | 0 | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 227K | -393K | -324K | -1.07M | -1.01M | -1.41M | -4.05M | -7.73M | -16.98M |
| Net Change in Cash | -809K▲ 0% | -14.04M▼ 1636.0% | 9.38M▲ 166.8% | -4.15M▼ 144.3% | -6.1M▼ 46.8% | 42.55M▲ 797.8% | -42.99M▼ 201.1% | 6.88M▲ 116.0% | 24.42M▲ 255.1% | -38.82M▲ 0% |
| Free Cash Flow | -21.47M▲ 0% | -15.35M▲ 28.5% | -29.89M▼ 94.7% | -22.36M▲ 25.2% | -20.78M▲ 7.1% | -23.44M▼ 12.8% | -38.28M▼ 63.3% | -26.52M▲ 30.7% | -20.69M▲ 22.0% | -28.53M▲ 0% |
| FCF Margin % | -71.89% | -37.89% | -105.47% | -189.75% | -112.57% | -105.42% | -103.31% | -37.78% | -22.98% | -14.52% |
| FCF Growth % | -30.16% | 28.51% | -94.72% | 25.18% | 7.07% | -12.81% | -63.29% | 30.73% | 21.98% | 55.97% |
| FCF per Share | -4.66 | -3.08 | -5.19 | -3.57 | -2.50 | -1.92 | -2.41 | -1.02 | -0.43 | -0.43 |
| FCF Conversion (FCF/Net Income) | 1.26x | 0.85x | 0.88x | 0.52x | 0.71x | 0.78x | 0.77x | 0.50x | 0.49x | 0.42x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MDXH Key Ratios
MDxHealth S.A. (MDXH) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -27.16% | -25.52% | -67.84% | -119.99% | -224.16% | -109.96% | -156.7% | -521.7% | -345.31% | -2187.37% |
| Return on Invested Capital (ROIC) | -51.57% | -36.55% | -89.09% | -184.4% | -281.69% | -414.04% | -151.35% | -68.66% | -68.42% | -68.42% |
| Gross Margin | 66.17% | 74.81% | 58.88% | -1.22% | 43.58% | 47.5% | 51.87% | 62.58% | 61.23% | 63.83% |
| Net Margin | -44.11% | -30.33% | -114.51% | -365.72% | -155.27% | -130.41% | -118.86% | -61.4% | -42.28% | -34.39% |
| Debt / Equity | 0.01x | 0.02x | 0.01x | 0.56x | 2.71x | 0.33x | 4.27x | 5.72x | 4.05x | 4.05x |
| Interest Coverage | - | -100.61x | -391.44x | -83.66x | -17.58x | -14.32x | -13.82x | -4.73x | -3.24x | -1.36x |
| FCF Conversion | 1.26x | 0.85x | 0.88x | 0.52x | 0.71x | 0.78x | 0.77x | 0.50x | 0.49x | 0.42x |
| Revenue Growth | 70.99% | 35.63% | -30.04% | -58.41% | 56.64% | 20.47% | 66.62% | 89.43% | 28.29% | 83.19% |
MDXH Frequently Asked Questions
MDxHealth S.A. (MDXH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
MDxHealth S.A. (MDXH) reported $196.5M in revenue for fiscal year 2024. This represents a 37253% increase from $0.5M in 2004.
MDxHealth S.A. (MDXH) grew revenue by 28.3% over the past year. This is strong growth.
MDxHealth S.A. (MDXH) reported a net loss of $67.6M for fiscal year 2024.
Dividend & Returns
MDxHealth S.A. (MDXH) has a return on equity (ROE) of -345.3%. Negative ROE indicates the company is unprofitable.
MDxHealth S.A. (MDXH) had negative free cash flow of $28.5M in fiscal year 2024, likely due to heavy capital investments.
Explore More MDXH
MDxHealth S.A. (MDXH) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates